For decades, the medical establishment has told patients with spinal cord injuries or diseases like multiple sclerosis that damaged nerves in the central nervous system do not grow back. That wall may finally have a crack in it.
Researchers at the University of Cambridge have built a living model of a human brain and spinal cord, grown from stem cells, and watched it do something textbooks said was impossible. Axons — the long fibers that carry electrical signals between neurons — grew across a gap between separate brain and spinal cord organoids, connected, and formed a working circuit. That circuit was strong enough to trigger muscle contractions.
The organoids are pea-sized. The team kept them physically apart in the lab. The axons bridged the space anyway.
This is not a rodent study. Most prior research on nerve regeneration relied on mice or rats, whose biology differs from humans in critical ways. The Cambridge team used human tissue from the start. That alone shifts the ground under the field.
The lead researcher, Andras Lakatos, and his team found something else. Human neurons have a built-in timer. Until roughly day 150 of development, damaged axons can regrow. After that, a biological switch flips. A network of genes activates and sharply shuts down the cells’ regenerative ability.
They identified the gene network driving that switch. Then they blocked its key regulators. The neurons regained their ability to grow axons.
That part of the work is basic science. But it points directly at a clinical target.
The team also tested an existing drug called lynestrenol. It improved axon regrowth in their experiments. Lakatos has said lynestrenol is unlikely to be the final clinical answer. But the fact that an already-approved drug had any effect at all suggests a faster path to human trials than starting from scratch.
The study was published in Cell Reports. It is a technical paper. But its implications are blunt. Spinal cord injury, motor neurone disease, multiple sclerosis — these conditions involve nerve damage that medicine has largely written off as permanent. This work challenges that assumption directly.
There is a long way from a pea-sized organoid in a dish to a human patient. The model does not replicate the full complexity of a living spinal cord. Scar tissue, immune responses, and the sheer scale of a human injury are not present in the lab system. The researchers know this.
But the model does something no animal model could do. It shows that human neurons, when directly targeted, can regenerate. That was not known before. It was assumed they could not. The assumption now has evidence against it.
The timing matters. The gene switch they identified kicks in around day 150 of development. That is roughly the midpoint of a human pregnancy. It suggests that the regenerative capacity is lost as the nervous system matures and stabilizes. Finding a way to turn that switch back on in adults is the next challenge.
Lakatos’ team has already shown it can be done in a dish. The next step is translating that into a therapy that works inside a living body. That step will take years. But the direction is now clear.
For patients with conditions that were untreatable, that direction alone is news.
